Haematopathology Slide Seminar FRCPath Part 2 Surgical Pathology Course, Manchester Dr A Chaturvedi /Dr L Menasce GM-HCDP, Consultant Histopathologist, Christie Hospital, Manchester, UK
The Christie NHS Foundation Trust
Neoplastic Haematopathology– clinical & laboratory considerations and their diagnostic/ therapeutic implications (1,2,3) Role of the histopathologist– 1. establish diagnosis (consider pitfalls) exclude non-neoplastic haematolymphoid processes inflammatory (dermatopathic LA); immunological (Kikuchi; lupus); infection (infectious mononucleosis (IM) in nodes, toxoplasma); megaloblastic anaemia in trephines (not covered – refer to extra slides); significance of granulomas (assess background lymphoid tissue), and, exclude non-haematolymphoid pathology [ e.g. metastasis- signet] 2. Guide/direct further management (e.g. advise on repeat sampling; material for flow-cytometry; local practices – FNA vs core vs excision) 3. Efficiency – time (rapid turnaround), cost See Ref. 1 (a&b): RCPath documents Ref. 2: IOG guidance Ref. 3: BLPG
The Christie NHS Foundation Trust
Overview Clinical information •
Age / Sex / Ethnic origin
• • •
Clinical presentation Site(s), Size and distribution of enlarged lymph nodes/ spleen/ cutaneous/ other Course of disease
• • • •
Area of residence/history of travel Drug history Past medical history Presence of or absence of immunosuppression HIV status/ History of transplant/ Autoimmune disorders/ Drugs/ Concurrent diseases
• •
Haematological laboratory findings - increased or decreased counts/ abnormal forms Serological studies- autoantibodies
•
Clinical differential diagnosis The Christie NHS Foundation Trust
Clinical context matters!
MIB1 CD20
CD20
EBV The Christie NHS Foundation Trust
Reference books
Swerdlow SH, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised Fourth Edition, Volume 2. Lyons: (IARC), 2017. Elder DE, et al. WHO Classification of Skin Tumours. Fourth Edition, Volume 11. Lyons: (IARC), Sept 2018.
The Christie NHS Foundation Trust
Histological assessment • Systematic approach • Thorough understanding of the normal cellular compartments and architecture (lymph node/ skin/ spleen/ mucosa/ bone marrow/other)
The Christie NHS Foundation Trust
lymph node : Size/ Capsule Architecture Sinus Follicles (B-cells) inter-follicular or paracortex (T-cells) Medulla (vessels), stromal elements etc.
(vessels)
Follicles: Germinal centre (B cells)
Mantle zone (B cells) Marginal zone (B cells)
The Christie NHS Foundation Trust
Types of Architectural patterns • • • • • • •
Diffuse (effaced) Nodular/ follicular Mantle Marginal Inter-follicular/paracortical Sinusoidal Heterogeneous
The Christie NHS Foundation Trust
‘Non-specific’/ Reactive lymph node patterns
• FOLLICULAR AND NODULAR PATTERNS Follicular Hyperplasia
Autoimmune Disorders (Rheumatoid Arthritis) Castleman’s Disease, Hyaline Vascular Type (Angiofollicular Lymphoid Hyperplasia) Progressive Transformation of Germinal Centers
The Christie NHS Foundation Trust
Reactive lymph nodal patterns ‘Non-specific’ • PREDOMINANTLY SINUS PATTERN Sinus Histiocytosis
Histiocytic Expansion Due to a Specific Cause (Storage Disease, Lymphangiogram, Prosthesis, Whipple’s Disease) Vascular Transformation of Sinuses Hemophagocytic Lymphohistiocytosis
The Christie NHS Foundation Trust
Reactive/ ‘Non-specific’ lymph nodal patterns INTERFOLLICULAR OR MIXED PATTERNS Paracortical Hyperplasia and Dermatopathic Reaction Granulomatous Lymphadenitis Immunoglobulin G4–Related Lymphadenopathy (IgG4 plasma cells (>100 per high-power field) and IgG4/IgG ratio (>40%))
Kimura’s Disease Toxoplasmic Lymphadenitis Systemic Lupus Erythematosus Kikuchi’s Lymphadenitis (Kikuchi-Fujimoto Lymphadenitis, Histiocytic Necrotizing Lymphadenitis) Kawasaki’s Disease (Mucocutaneous Lymph Node Syndrome) Inflammatory Pseudotumor Bacillary Angiomatosis The Christie NHS Foundation Trust
Reactive lymph nodal patterns ‘Non-specific’ DIFFUSE PATTERN Infectious Mononucleosis
Cytomegalovirus Infection Herpes Simplex Lymphadenitis Dilantin-Associated Lymphadenopathy
The Christie NHS Foundation Trust
Reactive lymph nodal patterns ‘Non-specific’ • Follicular hyperplasia • Mantle zone expansion • Marginal zone expansion/ monocytoid B-cell collections • Paracortical hyperplasia • Reactive immunoblastic proliferations • Sinus histiocytosis • Plasma cell infiltrates
The Christie NHS Foundation Trust
Assessment •
Differential diagnosis
•
Ancillary studies
1. 2. 3. 4.
Histochemical stains (rare) Immunohistochemistry Cytogenetics and molecular studies Flow cytometry
• Definitive diagnosis depends on morphological findings, clinical context and ancillary studies
The Christie NHS Foundation Trust
LR2 – 5648-09 • 30 years; male
• Persistent lymphadenopathy • HIV+
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
LR2 – 5648-09
• HIV-associated lymphadenopathy • florid follicular hyperplasia with follicle lysis
The Christie NHS Foundation Trust
LR2 – 5648-09 • HIV-associated lymphadenopathy (contd) • StagesType A: florid follicular hyperplasia Type B: florid follicular hyperplasia with follicle lysis Type C: lymphocyte depletion • p24 antigen by IHC in dendritic cells
The Christie NHS Foundation Trust
LR6 – 674-08 • 20 years; Female
• Groin lymph node
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
LR6 – 674-08 • Reactive lymph node with follicular and paracortical hyperplasia • Dermatopathic-lymphadenitis-like changes
The Christie NHS Foundation Trust
LR6 – 674-08 • “Dermatopathic-lymphadenitis-like changes” • Paracortical hyperplasia – IDC’s (S100+), LC’s (S100, CD1a, CD207 +) and melanin-laden macrophages • Consider TCR gene-rearrangement clonality testing [early involvement by MF/SS)
The Christie NHS Foundation Trust
LR13-1 • Female 31; • persistent palpable left posterior triangle lymph node
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
• CD3 The Christie NHS Foundation Trust
• MPO
The Christie NHS Foundation Trust
Kikuchi-Fujimoto lymphadenopathy (Histiocytic Necrotizing Lymphadenitis) •
Predominance in young adults (esp., women and Far east Asian descent)
• •
Cervical lymph nodes; Mild systemic symptoms (fever, sore throat, myalgia) Benign course, spontaneous remission
• • • • •
Lymph node slightly enlarged, partly preserved architecture, patchy necrosis, marked apoptosis, nuclear debris Proliferative, necrotising, xanthomatous phases Aggregates of histiocytes with crescentic nuclei (MPO+) Activated T lymphocytes (immunoblasts), predominant cytotoxic CD8+ Plasmacytoid dendritic cells (CD123 positive)
•
Absence of neutrophils and eosinophils
The Christie NHS Foundation Trust
Other example proliferative The Christie NHS Foundation Trust
Other example - necrotic
The Christie NHS Foundation Trust
Other example xanthomatous The Christie NHS Foundation Trust
Kikuchi-Fujimoto lymphadenopathy differential diagnosis • Systemic lupus lymphadenitis
• Necrotising granulomatous lesions (TB, histoplasmosis, leprosy, cat-scratch) • Acute EBV infection • Allergic reactions • Necrosis in lymphoma • Non-Hodgkin lymphoma The Christie NHS Foundation Trust
LR 14 - 2 • Male 31y; inguinal lymph node
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
HSV
The Christie NHS Foundation Trust
Herpes simplex virus lymphadenitis • Usually associated with disseminated infection and rash • More common in immunosupressed persons • Rarely localised, mainly inguinal • Viral inclusions
The Christie NHS Foundation Trust
LR9
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
LR9 • Toxoplasmosis
The Christie NHS Foundation Trust
Toxoplasmosis vs HIV adenopathy • • • •
Geographic lymphoid follicles are seen in both. Monocytoid B-cell hyperplasia are seen in both. Intrafollicular microgranulomas commoner in toxoplasmosis. Paracortical polykaryons in some cases of HIV.
• • • •
Loss of IgM, IgD positive mantle in HIV. Reversal of CD4:CD8 ratio in HIV. HIV p24 staining of FDC meshworks in HIV. Antitoxoplasma immunohistochemistry is of no value in toxoplasmic lymphadenitis, and cysts are v. v. v. rare!
• Coincident pathologies in HIV. • Some patients with HIV are infected with toxoplasma! The Christie NHS Foundation Trust
LR5 – 1290-10 • 35 years; male
• Right posterior triangle lymph nodes
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
LR5 – 1290-10 • Tuberculous lymphadenitis.
• AFB identified on ZN stain
The Christie NHS Foundation Trust
Granulomatous lymphadenopathy • • • • • •
Tuberculosis Sarcoidosis Lymphogranuloma venereum Tularaemia Cat Scratch disease Toxoplasmosis
Neoplastic • Lymphoma – T-cell lymphoma -Hodgkin lymphoma -Other lymphomas • Non-haematologic malignancies – seminoma etc
The Christie NHS Foundation Trust
LR16 - 4 • Female 44y; • mediastinal mass ?thymoma
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
• CD21
The Christie NHS Foundation Trust
IgM
IgD
The Christie NHS Foundation Trust
Castleman lymphadenopathy hyaline vascular type • • • •
More common Younger patients Frequently asymptomatic Isolated lymph node mass (Often mediastinal)
• Numerous small lymphoid follicles • Lollipop follicle • Hyaline deposits in germinal centres; expanded FDCs meshworks; atypia in FDCs (clonal abnormalities have been detected at molecular level) • Concentric layering of lymphocytes • Interfollicular vascular hyperplasia; hyaline sclerosis The Christie NHS Foundation Trust
Castleman’s Disease Hyaline-Vascular variant
Plasma Cell variant
•
• • •
• •
•
Younger patients (children and young adults) Isolated lymph node mass (unicentric) Often mediastinal (abdominal, retroperitoneal) Frequently asymptomatic
• •
•
Pathogenesis: FDC abnormalities: Increased local VEGF EGFR expression by FDC Clonal cytogenetic abnormalities FDC dysplasia / sarcoma
•
Management: Excision, RT
•
Mixed type? Some overlapping morphological features
•
Age variable Multicentric > unicentric Peripheral and/or central lymphadenopathy Systemic symptoms usually present Pathogenesis “IL6 syndrome” (human IL6, viral IL6, VEGF, others?) Plasma cell disorders (myeloma, POEMS) HHV8, “Plasmablastic variant” Autoimmune diseases; Unknown Management varies according to clinical syndrome immunomodulation,anti-IL6, anti-CD20, HAART, CT, PSCT
The Christie NHS Foundation Trust
Castleman’s disease Plasma cell variant Separate example
L
K The Christie NHS Foundation Trust
LR 15 - 3 • Female 67y; • lymph node right posterior triangle; • enlarged neck lymph nodes plus swelling post nasal space
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
S100 protein The Christie NHS Foundation Trust
Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman) • Mean age 20 (new born-elderly) • Usually cervical lymphadenopathy but other sites including extra-nodal disease • Lymphadenopathy of long duration, usually spontaneous regression • Dilatation of sinuses • Large histiocytic cells(CD68, S100+) with abundant eosinophilic cytoplasm containing vacuoles with engulfed lymphocytes (emperipolesis) • Numerous polyclonal plasma cells • ?aetiology; defective phagocytosis? subset familial syndrome (mutation in SLC29A3) The Christie NHS Foundation Trust
LR4 – 4647-09 • 61 years; female
• Swelling submental region; • 6 months duration; • painless and slowly growing
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust CD20
The Christie NHS Foundation Trust CD3
The Christie NHS Foundation Trust CD5
CD23
The Christie NHS Foundation Trust
LR4 – 4647-09 Positive • • • •
CD20 CD5 CD23 BCL2
Negative • CD3 • CD10 • Cyclin D1
Ki-67 ~ 5%
The Christie NHS Foundation Trust
LR4 – 4647-09 • Chronic lymphocytic leukaemia / small lymphocytic lymphoma
The Christie NHS Foundation Trust
CLL - Transformation • Richter transformation (~3%) • Clonally related or unrelated (about a half each)
• Classic DLBCL-type • Hodgkin lymphoma-like (~0.5%) • Prolymphocytic transformation (frequency not known)
The Christie NHS Foundation Trust
Related discussion LYMPHOID NEOPLASMS
NHL Mature B-cell neoplasms Indolent CLL/SLL, FL (incl. cutaneous), Extra-nodal MZL of MALT(other MZL) LPL, HCL Plasma cell neoplasms [MGUS/PC Myeloma/others], Intermediate Mantle CL
High grade DLBCL, NOS (GC vs. post GC), variants Plasmablastic L, PEL Burkitt lymphoma (and similar entities)
The Christie NHS Foundation Trust
LYMPHOID NEOPLASMS NHL : Mature B-cell neoplasms; CLL/SLL, FL (incl. cutaneous), MantleCL, MZL
CLL/SLL small lymphocyte, round nucleus, clumped chromatin inconspicuous nucleolus
Follicular Lymphoma
Marginal Zone Lymphoma
two cell types: centrocytes and centroblasts
Small bland ‘monocytoid’ Exclude other indolent NHL CD43; IRTA1, MNDA; clonality
Mantle Cell Lymphoma (MCL) N.B. : Transformation in all indolent NHL (i.e. block and assess entire node) 1. CLL - Richter’s 2. FL grade : centroblasts/hpf: 0-5,6-15, >15 (+/centrocytes); follicular/ diffuse 3. Blastoid var MCL
uniform population small to medium, cleaved nuclei
The Christie NHS Foundation Trust
LYMPHOID NEOPLASMS (contd) NHL : Mature B-cell neoplasms;
CLL/SLL, FL (incl. cutaneous), MantleCL, MZL
CLL: •‘nodular’ • Proliferation centres •Use of CD21/CD23- dendritic markers
The Christie NHS Foundation Trust
LR3 – 101-08 • 40 years; male
• Right cervical lymph node
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust CD20
The Christie NHS Foundation Trust CD3
CD5
CD3
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust CD23
The Christie NHS Foundation Trust BCL2
Cyclin D1 The Christie NHS Foundation Trust
Cyclin D1 The Christie NHS Foundation Trust
LR3 – 101-08 Positive • • • •
CD20 CD5 Cyclin D1 BCL2
Negative • • • •
CD3 CD23 CD10 p53
The Christie NHS Foundation Trust
LR3 – 101-08 • Mantle cell lymphoma
The Christie NHS Foundation Trust
Mantle Cell Lymphoma • Most are associated with t(11;14) and overexpression of cyclin D1. • A small proportion of cases are cyclin D1 negative; these show overexpression of cyclin D2 and cyclin D3.
• SOX11
The Christie NHS Foundation Trust
Mantle Cell Lymphoma • malignancy of naïve B-cells. • associated with a relatively poor prognosis. • a small proportion have mutations in the Ig gene - these patients have better prognosis.
The Christie NHS Foundation Trust
Mantle Cell Lymphoma • Patterns: Nodular, mantle zone and diffuse. • Variants: Blastoid variant (>10 mitosis/ 10hpf Pleomorphic blastoid CLL-like
The Christie NHS Foundation Trust
Case LR8 • 50 years; male
• lymph node left groin enlarged
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust CD20
The Christie NHS Foundation Trust CD10
The Christie NHS Foundation Trust BCL6
The Christie NHS Foundation Trust BCL2
The Christie NHS Foundation Trust CD21
The Christie NHS Foundation Trust CD23
The Christie NHS Foundation Trust Ki-67
Case LR8 Positive • • • • •
CD20 CD10 BCL6 CD23 BCL2
Negative • CD3 • CD5 • CD21
Ki-67 <25%
The Christie NHS Foundation Trust
Case LR8 • Follicular lymphoma, grade 1
The Christie NHS Foundation Trust
Follicular Lymphoma Centrocytes + Centroblasts Number of centroblasts/hpf <5
6-15
Only Centroblasts
Follicular grade 3b
>15
1 2 3a Follicular grade
The Christie NHS Foundation Trust
Related discussion - LYMPHOID NEOPLASMS NHL : Mature B-cell neoplasms;
CLL/SLL, FL (incl. cutaneous), MantleCL, MZL
Follicular Lymphoma (FL) from Follicular Hyperplasia Characteristic
Specificity for FL
Frequency in FL
Centrocytes Diagnostic predominate in follicles
High
Centrocytes present between follicles
Diagnostic
High
Diagnostic
Moderate
Highly suggestive
High
Highly suggestive
Moderate
Vascular invasion by centrocytes Close packing of follicles Diffuse areas or sclerosis
Follicles extend beyond Highly suggestive nodal capsule
High
Mantle zone absent
Suggestive
High
“Starry sky” cells absent in follicles
Suggestive
High
Mantle zone present
Not helpful
Low
Some reactive follicles present
Not helpful
Low
Size, shape, uniformity of follicles
Not helpful
—
“Cracking” artefact or compression of reticulin
Not helpful
—
The Christie NHS Foundation Trust
LR10 – 4461-10 • 31 years; male
• Left axillary lymphadenopathy
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust CD20
The Christie NHS Foundation Trust CD20
The Christie NHS Foundation Trust CD20
The Christie NHS Foundation Trust CD21
The Christie NHS Foundation Trust EMA
LR10 – 4461-10 Positive • • • •
CD20 EMA BCL2 Lambda light chain restriction
Negative • • • • •
CD15 CD30 CD3 IgD EBV-LMP-1
Prominent CD57 positive T-cell infiltrate in the background; rosettes
The Christie NHS Foundation Trust
LR10 – 4461-10 • Nodular lymphocyte predominant Hodgkin lymphoma
The Christie NHS Foundation Trust
Nodular Lymphocyte Predominant HL - A Distinct Entity •
Unimodal age distribution - usually 4th or 5th decades
•
Male predominance
•
Stage I or Stage II disease
•
B-symptoms – uncommon
•
Cervical and inguinal lymph node involvement is common
•
Mediastinal involvement is uncommon
The Christie NHS Foundation Trust
Nodular Lymphocyte Predominant HL – A Distinct Entity • Associated with progressively transforming germinal centres • About 3-5% progress to NHL - diffuse large B-cell type • Frequent multiple relapses • Good survival • ‘Wait & Watch’ in stage I
The Christie NHS Foundation Trust
LR1 – 309-10 • 22 years; female
• Right neck node
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust CD20
The Christie NHS Foundation Trust CD3
The Christie NHS Foundation Trust CD30
The Christie NHS Foundation Trust CD15
LR1 – 309-10 Positive • • • •
CD20 (uneven) CD15 CD30 BCL2
Negative • CD45 • CD3 • EBV-LMP-1
The Christie NHS Foundation Trust
LR1 – 309-10 • Nodular Sclerosis Classical Hodgkin lymphoma, BNLI grade 1
The Christie NHS Foundation Trust
Sub-classification of Nodular sclerosis classical Hodgkin Lymphoma BNLI 1985 • Grade I – • Lymphocyte predominance or • mixed cellularity without pleomorphic RS cells • predominance of bland fibrohistiocytes with a minority of RS cells • Grade II – • mixed cellularity with pleomorphic RS cells • 25% of nodules with a high proportion of RS cells and variants • lymphocyte depletion
The Christie NHS Foundation Trust
Hodgkin Lymphoma Nodular Lymphocyte Predominant HL
Classical HL Mixed Cellularity
Grade 1 Nodular Sclerosis Grade2 Lymphocyte-rich Lymphocyte Depleted
The Christie NHS Foundation Trust
Diagnostic Criteria -
Hodgkin Lymphoma Classical type
Nodular LP •
Classical RS cell not seen; “popcorn” cells seen
•
Classical RS cell often seen
•
Background cells - admixture of Bcells and T-cells OR predominantly B-cells; T cells rosettes
•
Background cells - activated T cells; T cell rosettes
•
Eosinophils & plasma cells scanty
•
Eosinophils & plasma cells often seen
•
Often rich in histiocytes
•
Histiocytes less conspicuous
Positive
1. 2. 3. 4. 5.
CD45+ CD20+ Oct-2+ BOB.1+ MUM-1+/–
Negative
1. 2. 3. 4. 5.
CD15− CD30− BCL2− CD10− EBV−
Positive
Negative
1.CD30 (>90%) 2.CD15 (75%-85%) 3.BSAP (PAX5) 4.IRF4/MUM-1 5.CD20 −/+ 6.LMP-1 (20%-50%)
1.CD45 2.EMA 3.ALK1 4.CD79a (rarely +) 5.BOB.1 6.Oct-2 −/+
The Christie NHS Foundation Trust
LR7 – 8941-09 • 38 years; Male
• HIV+ • Left axillary mass
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust CD20
The Christie NHS Foundation Trust CD3
The Christie NHS Foundation Trust CD10
The Christie NHS Foundation Trust BCL6
The Christie NHS Foundation Trust BCL2
The Christie NHS Foundation Trust Ki-67
LR7 – 8941-09 Positive • • • • •
CD20 CD79a CD10 BCL6 EBER
Negative • • • • •
CD3 CD5 CD138 MUM1 BCL2
Ki-67 ~ 100% IGH/MYC and CMYC rearrangement positive; no evidence of IGH/BCL2 and BCL6 rearrangement
The Christie NHS Foundation Trust
LR7 – 8941-09 • Burkitt lymphoma
The Christie NHS Foundation Trust
Related discussion -LYMPHOID NEOPLASMS NHL :Mature B-cell neoplasms –
DLBCL, NOS (GC vs. post GC) and variants;; Burkitt lymphoma
Burkitt’s lymphoma
DLBCL
large vesicular nuclei, prominent nucleoli, basophilic cytoplasm and easily found mitotic figures; heterogeneous cell population
medium-sized, monotonous and somewhat uniform appearance; starry sky
feature
BL
Expression of CD19, Positive CD20, CD22, CD79a
Most cases positive
CD10 expression
Positive
Variably positive; defines GCB subtype of DLBCL
BCL6 expression
Positive
Most cases positive
Negative
60%-70% positive, mostly within ABC subtype
Bright CD38
Positive
CD38 may be positive, but often dim
EBV-EBER
Positive (15%- Usually 30%)† negative
Cytogenetics
t(8;14) or variant
BCL2 expression
CD10− CD10+
BCL6+ IRF4/MUM-1−
Germinal center B-cell type (GCB)
BCL6+ IRF4/MUM-1+
BCL6−
Non–germinal center Bcell type (non-GCB)
DLBCL
+, expression in >30% of tumor cells Hans Algorithm Molecular
MYC rearrangement to IG partner
MYC translocation in 5%-8% of de novo DLBCLs
LR18 - 6 • Female 18y; axillary lymph node
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
CD20 The Christie NHS Foundation Trust
CD3 The Christie NHS Foundation Trust
• CD30
The Christie NHS Foundation Trust
• EMA
The Christie NHS Foundation Trust
• ALK
The Christie NHS Foundation Trust
Anaplastic large cell lymphoma Alk positive • Young adults • Peripheral lymph nodes affected; Skin can be involved
• Partial nodal involvement • Paracortical areas (T- zone) and sinuses involvement • Follicles and germinal centres spared • Cohesive cells, cords and sheets, anaplastic large cells, pleomorphic bizarre, reniform; wreath-like, embryo-like nuclei (hallmark cell) • T- cell phenotype (often CD3 -) • Translocation t(2; 5)(p23;q35) • Chimeric protein NPM– ALK detected by antibody ALK-1(nuclear and cytoplasmic staining) • variants The Christie NHS Foundation Trust
LR19 - 7 • Female 86y; bx right supraclavicular node. Previous bx, mostly necrotic; ? metastatic
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
EMA
The Christie NHS Foundation Trust
CD30 The Christie NHS Foundation Trust
CD79a
The Christie NHS Foundation Trust
CD20
The Christie NHS Foundation Trust
PAX5 The Christie NHS Foundation Trust
Kappa
Lambda
The Christie NHS Foundation Trust
EBER The Christie NHS Foundation Trust
ALK
The Christie NHS Foundation Trust
ALK positive large B-cell lymphoma • Rare (less than 1% of DLBCL) • Mainly involves lymph nodes; may present as a mediastinal mass or involve extranodal sites • Most patients present with advanced stage disease (III/IV)
• Sinusoidal growth pattern; large immunoblast-like cells, plasmablastic, atypical multinucleated cells • • • • •
Alk positive (cytoplasmic granular pattern), t(2;17)(p23;q23) Clathrin-ALK fusion protein EMA positive with cytoplasmic and membranous pattern negative for CD20,CD79a, CD30 (weak focal) light chain restricted The Christie NHS Foundation Trust
Differential diagnosis • • • •
Metastatic carcinoma Metastatic seminoma Metastatic melanoma Plasmablastic lymphoma
The Christie NHS Foundation Trust
LR20 - 8 Female 66y;lump right forearm, known CLL
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
LCA/CD45
The Christie NHS Foundation Trust
CD20
The Christie NHS Foundation Trust
CD3
The Christie NHS Foundation Trust
CD43 The Christie NHS Foundation Trust
LYSOZYME
The Christie NHS Foundation Trust
CD11c
The Christie NHS Foundation Trust
PGM-1 The Christie NHS Foundation Trust
S-100
The Christie NHS Foundation Trust
Melan-A
The Christie NHS Foundation Trust
Myeloid sarcoma • Tumour mass of myeloid blasts with or without maturation at a site other than the bone marrow • Syn.: Extra-medullary myeloid tumour, granulocytic sarcoma, chloroma • Skin, lymph node, GI, bone, soft tissue, testis • Myeloblasts with or without features of promyelocytic or neutrophilic maturation • IHC panel: CD68, lysozyme, CD43, MPO, CD117, CD34, CD56, glycophorin, CD4, CD14, CD11c, CD163, CD45 CD30; CD123 • May occur de novo, precede or coincide with AML or represent blastic transformation of MDS, MPN, MDS/MPN The Christie NHS Foundation Trust
Differential diagnosis • Non-Hodgkin lymphoma • Melanoma, neuroendocrine carcinoma
The Christie NHS Foundation Trust
Case xxx • Female 50Y • enlarged inguinal lymph node
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
CD3
CD2
CD79a
CD7
CD20
The Christie NHS Foundation Trust
CD4
CD8
PD1
EBER
The Christie NHS Foundation Trust
CD21 The Christie NHS Foundation Trust
Angioimmunoblastic T cell lymphoma • Peripheral T-cell lymphoma • CD4 positive follicular helper T cell • Frequent association with EBV • Clinical: Systemic disease at presentation (advanced stage); generalised lymphadenopathy; hepato-splenomegaly; skin rash; pruritus; pleural effusion; arthritis; ascites;
polyclonal hypergammaglobulinaemia; circulating immune complexes; haemolytic anaemia; positive rheumatoid factor; and anti–smooth muscle antibodies The Christie NHS Foundation Trust
Angioimmunoblastic T-cell lymphoma • Lymph node architecture often partially effaced and peripheral cortical sinuses may be spared
• Marked proliferation of arborising high endothelial venules; increased follicular dendritic cell meshworks • Polymorphic infiltrate, small, medium sized; pale cytoplasm (PD1, CD10,CX CL13, FOXP3 +); reactive lymphocytes, eosinophils, plasma cells and histiocytes; Reed-Sternberglike cells
• Expansion of B-immunoblasts in the paracortex; EBV positive; may progress to EBV positive DLBCL. The Christie NHS Foundation Trust
Other example Peripheral T-cell lymphoma NOS The Christie NHS Foundation Trust
Peripheral T-cell lymphoma NOS- CD3 The Christie NHS Foundation Trust
Peripheral T-cell lymphoma CD15 The Christie NHS Foundation Trust
Peripheral T-Cell Lymphoma, Not Otherwise Specified • All mature T-cell neoplasms lacking specific features that would allow categorization in any better-defined WHO classification subtype of postthymic T-cell lymphoma/leukemia • Other categories of T-cell lymphoma must be excluded before a diagnosis of PTCL, NOS is established • Unlikely to constitute only one entity
• Rare overall but represent the most common PTCL category in North America and Europe • Affect older adults (median age, 60 years), but children can also be affected • Most patients present with nodal involvement, but any site may be affected. The Christie NHS Foundation Trust
Peripheral T cell lymphoma NOS • CD3+, CD4+ > CD8+, TCRαβ+ neoplastic T cells • Aberrant T-cell immunophenotype • Cytotoxic immunophenotype uncommon Molecular Genetics • Monoclonal TCR gene rearrangements in 90% to 100% of cases • Monoclonal or oligoclonal IgH gene rearrangement may be present Cytogenetics • Complex clonal chromosome aberrations frequent • Rare recurrent translocations, t(5;9) (SYK-ITK), in the follicular variant
The Christie NHS Foundation Trust
Lymphoepithelioid variant
T-zone variant
The Christie NHS Foundation Trust
Fellowship tumour pathology The Christie School of Oncology The Christie, Manchester UK • • • • • • •
Haemato-lymphoid Urology Soft Tissue Skin tumours Gynaecological GI Neuroendocrine lia.menasce@christie.nhs.uk, patrick.Shenjere@christie.nhs.uk • pedro.oliveira@christie.nhs.uk • Anshuman.chaturvedi@christie.nhs.uk The Christie NHS Foundation Trust
Extra slides
The Christie NHS Foundation Trust
Tumours of Haematopoietic and lymphoid tissues (ref.4) MYELOID NEOPLASMS - Myeloproliferative Neoplasms (CML,PV, ET, PM, mastocytosis. others) -
Myeloid & Lymphoid neoplasms with eosinophils & PDGFR/ FGFR abnormality
-
Myelodysplastic/MPN (CMML and others)
-
MD Syndromes/ neoplasms (RCUD, RCMD, RARS, RAEB, isolated 5q, others)
-
Acute myeloid leukaemia (recurrent genetic abn. [APML]/ MDS-/ Therapyrelated, AML-NOS, myeloid sarcoma, Blastic plasmacytoid dendritic)
-
Acute leukaemia, ambiguous lineage See Ref. 4: WHO blue book
The Christie NHS Foundation Trust
Tumours of Haematopoietic and lymphoid tissues (ref.4) LYMPHOID NEOPLASMS NHL Precursor lymphoid neoplasms (B- and T- Lymphoblastic leukaemia/lymphoma, NOS; other) Mature B-cell neoplasms INDOLENT= CLL/SLL, FL (incl. cutaneous), Mantle CL, Extra-nodal MZL of MALT(other MZL), LPL,HCL, Plasma cell neoplasms [Myeloma/others] HIGH-GRADE= DLBCL, NOS (GC vs. post GC) – subtypes, variants incl. Plasmablastic L, Primary effusion lymphoma Burkitt lymphoma (and similar entities) Mature T-cell neoplasms Extranodal NK/ T-cell lymphoma, nasal type (and others) Enteropathy-associated T-cell lymphoma, Cutaneous T-cell neoplasms including - MF, Sezary syndrome , Primary cut. CD-30 positive lymphoproliferative disorders (and others) Angioimmunoblastic T-cell lymphoma, ALCL (ALK positive and negative) , PTCL-NOS HL NLPHL cHL (NS-cHL, MC-cHL, LR-cHL, LD-cHL) Immunodeficiency associated lymphoproliferative disorders (HIV associated, PTLD, others)
HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS LCH, Dendritic cell sarcoma and others
The Christie NHS Foundation Trust See Ref. 4: WHO blue book
Histopathology - laboratory issues (1) 1. 2. 3.
4.
Bone marrow, Nodal and Extra-nodal neoplasia (tissue processing) Special stains – Trephine biopsy (Reticulin, Perl’s, Giemsa) Immunohistochemistry- CD markers (Initial panel); controls; uss Lymph nodes and trephines LCA : ?role (HL); CD20 (vs CD79a), CD3: B- & T-cell lineages CD21/ CD23: Dendritic meshwork; BCL-2: Follicle centre (role in FL vs reactive; other) Ki-67: G.C. polarity; proliferation (Burkitt’s vs DLBCL) ‘other’ NHL: CD5, CD23, cyclin-D1, CD10, BCL6, CD43, kappa, lambda, CD138 (CD56), TdT HL: CD30, CD15 ‘additional’ markers: CD4, CD8, CD7, CD56, Perforin, Granzyme, Alk-1, BOB-1, OCT-2, tryptase, DBA.44, CD103, CD2, CD25, PAX-5 , LMP-1, EBER-ISH Trephines MPO (myeloid), glycophorin (erythroid), vWF/ CD31, CD34 (monoblasts may be negative), CD117, TdT Genetics (specific translocations/ clonality studies): conventional cytogenetics (?role), FISH, RT-PCR
The Christie NHS Foundation Trust
See Ref. 1 (a&b): RCPath documents
LYMPHOID NEOPLASMS NHL Mature T-cell neoplasms Extranodal NK/ T-cell lymphoma, nasal type (and others) Enteropathy-associated T-cell lymphoma, Cutaneous T-cell neoplasms including – MF, Sezary syndrome , Primary cut. CD-30 positive lymphoproliferative disorders (and others) Angioimmunoblastic T-cell lymphoma, ALCL (ALK positive and negative) , PTCL-NOS
The Christie NHS Foundation Trust
LYMPHOID NEOPLASMS NHL : Mature T-cell neoplasms Extranodal NK/ T-cell lymphoma, nasal type (and others) broad cytologic spectrum - small medium or large blastic frequent necrosis, angiocentric growth, cytotoxic phenotype, strong association with Epstein-Barr virus (EBV) IHC: CD2+, surface CD3−, cytoplasmic CD3ε+, and CD56+ CD43 and CD45RO are commonly positive, and CD7 is occasionally expressed. CD4, CD5, CD8, TCRαβ, and TCRγδ are usually negative Ki-67 immunostaining is usually high (>50%) nearly consistent association with EBV- LMP1, EBER
Anaplastic large cell lymphoma (ALCL) usually large and have abundant cytoplasm and pleomorphic, often horseshoe-shaped nuclei. t(2;5)(p23;q35); variant translocations By definition, all ALCLs are positive for CD30. variably positive for CD45 and CD45RO one or more T-cell or natural killer (NK)-cell antigens; null-type CD3 negative in more than 75% ALK staining may be cytoplasmic, nuclear, and nucleolar,
The Christie NHS Foundation Trust
LYMPHOID NEOPLASMS NHL : Mature T-cell neoplasms EATL: tumour of intraepithelial lymphocytes varying degrees of transformation Usually large lymphoid cells classic form of EATL and the type II, or monomorphic, variant complication of celiac disease (gluten-sensitive enteropathy) / sporadically positive for CD3, CD7, CD103, and granzyme B; negative for CD4 and CD8 [type II EATL - tumour cells express CD3, CD8, CD56, and granzyme B]
The Christie NHS Foundation Trust
OTHER LYMPHOID NEOPLASMS • Immunodeficiency associated lymphoproliferative disorders (HIV associated, PTLD, others) HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS • LCH, Dendritic cell sarcoma and others
The Christie NHS Foundation Trust
Primary Cutaneous Lymphomas
Swerdlow SH, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised Fourth Edition, Volume 2. Lyons: (IARC), 2017. Elder DE, et al. WHO Classification of Skin Tumours. Fourth Edition, Volume 11. Lyons: (IARC), Sept 2018.
The Christie NHS Foundation Trust
Primary Cutaneous T-Cell Lymphomas
Quintanilla-Martinez L, et al. Non–Mycosis Fungoides Cutaneous T-Cell Lymphomas. Report of the 2011 Soc for Hematopathology/Eur Assoc for Haem Wkshp. Am J Clin Pathol 2013;139:491-514
The Christie NHS Foundation Trust
Primary Cutaneous T-Cell Lymphomas
Mycosis fungoides & Sézary syndrome - two closely related conditions; neoplastic T cells infiltrate the skin & circulate in peripheral blood
Jaffe E, et al (ed). Ch39. Mycosis Fungoides and Sézary Syndrome. In, Hematopathology (2nd edition) - Elsevier, 2017.
The Christie NHS Foundation Trust
Primary Cutaneous T-Cell Lymphomas
Mycosis fungoides - patch stage
Note: The diagnosis of mycosis fungoides is best established with the collaboration of a knowledgeable clinician, unless the histopathologic findings are unequivocal.
Jaffe E, et al (ed). Ch39. Mycosis Fungoides and Sézary Syndrome. In, Hematopathology (2nd edition) - Elsevier, 2017.
The Christie NHS Foundation Trust
Primary Cutaneous T-Cell Lymphomas Mycosis fungoides – patch and tumour stage
Note: CD30+ cells occur in some plaques of mycosis fungoides, but mostly in tumors that have anaplastic large cells; when CD30 is expressed on lesional lymphocytes that have undergone large cell transformation, it does seem to have prognostic significance
Jaffe E, et al (ed). Ch39. Mycosis Fungoides and Sézary Syndrome. In, Hematopathology (2nd edition) - Elsevier, 2017.
The Christie NHS Foundation Trust
Primary Cutaneous T-Cell Lymphomas (Non-mycosis fungoides)
Three types of primary cutaneous CD30+ lymphoproliferative disorders (LPDs) are recognized in the World Health Organization classification: • primary cutaneous anaplastic large cell lymphoma (C-ALCL), • lymphomatoid papulosis (LyP), and • borderline lesions.
Quintanilla-Martinez L, et al. Non–Mycosis Fungoides Cutaneous T-Cell Lymphomas. Report of the 2011 Soc for Hematopathology/Eur Assoc for Haem Wkshp. Am J Clin Pathol 2013;139:491-514
The Christie NHS Foundation Trust
Diagnostic challenges
Note: LyP and C-ALCL can coexist and probably represent a continuum of lesions. Detection of clonality does not indicate lymphoma as it occurs in LyP and pityriasis lichenoides. Histologic distinction of LyP from lymphoma can be extremely difficult, making clinical correlation imperative. The diagnosis is often obvious when one sees the patient. The correct diagnosis of LyP is essential to avoid overtreatment.
Quintanilla-Martinez L, et al. Non–Mycosis Fungoides Cutaneous T-Cell Lymphomas. Report of the 2011 Soc for Hematopathology/Eur Assoc for Haem Wkshp. Am J Clin Pathol 2013;139:491-514
The Christie NHS Foundation Trust
Diagnostic challenges
Quintanilla-Martinez L, et al. Non–Mycosis Fungoides Cutaneous T-Cell Lymphomas. Report of the 2011 Soc for Hematopathology/Eur Assoc for Haem Wkshp. Am J Clin Pathol 2013;139:491-514
The Christie NHS Foundation Trust
Diagnostic challenges
Quintanilla-Martinez L, et al. Non–Mycosis Fungoides Cutaneous T-Cell Lymphomas. Report of the 2011 Soc for Hematopathology/Eur Assoc for Haem Wkshp. Am J Clin Pathol 2013;139:491-514
The Christie NHS Foundation Trust
Diagnostic challenges
Quintanilla-Martinez L, et al. Non–Mycosis Fungoides Cutaneous T-Cell Lymphomas. Report of the 2011 Soc for Hematopathology/Eur Assoc for Haem Wkshp. Am J Clin Pathol 2013;139:491-514
The Christie NHS Foundation Trust
Primary Cutaneous B-cell Lymphomas - classification
in the revised WHO 2016 classification, PCFCL and PCDLBCL, LT are included as separate entities, as defined in the WHO-EORTC classification
Jaffe E, et al (ed). Ch20. Primary Cutaneous B-Cell Lymphomas. In, Hematopathology (2nd edition) - Elsevier, 2017.
The Christie NHS Foundation Trust
Primary Cutaneous B-Cell Lymphomas
Jaffe E, et al (ed). Ch20. Primary Cutaneous B-Cell Lymphomas. In, Hematopathology (2nd edition) - Elsevier, 2017.
The Christie NHS Foundation Trust
Primary Cutaneous B-Cell Lymphomas
Primary cutaneous marginal-zone lymphoma. A, Typical clinical presentation with multiple nodules on the back. B, Dense infiltrates throughout the dermis are shown. C, CD79a staining showing a predominance of B cells and reactive germinal centers D, Monotypic immunoglobulin G, kappa-positive plasma cells in the superficial dermis (kappa staining). E, Negative staining for lambda light chains.
Jaffe E, et al (ed). Ch20. Primary Cutaneous B-Cell Lymphomas. In, Hematopathology (2nd edition) - Elsevier, 2017.
The Christie NHS Foundation Trust
Primary Cutaneous B-Cell Lymphomas
• Primary Cutaneous Follicle-Center Lymphoma
• 10% of all cutaneous lymphomas and about 50% of primary CBCLs • indolent clinical course • perivascular and periadnexal, nodular or diffuse infiltrates with almost constant sparing of the epidermis • Variable European and US data: do not express BCL2 protein or show faint BCL2 staining in a minority of neoplastic B cells do not or rarely show the interchromosomal (14;18) translocation
Jaffe E, et al (ed). Ch20. Primary Cutaneous B-Cell Lymphomas. In, Hematopathology (2nd edition) - Elsevier, 2017.
The Christie NHS Foundation Trust
Primary Cutaneous B-Cell Lymphomas
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type (A), Clinical presentation with large tumors on the right lower leg (20% other sites) (B), Diffuse proliferation of centroblasts and immunoblasts (C) Tumor cells show strong reactivity for CD20 [note- activated B-cell (ABC)-type DLBCL]
(D) immunoglobulin M and (E) MYC
Jaffe E, et al (ed). Ch20. Primary Cutaneous B-Cell Lymphomas. In, Hematopathology (2nd edition) - Elsevier, 2017.
The Christie NHS Foundation Trust
Bone marrow trephine reporting Adequacy – at least 1.5 cm in length and obtained at right angles to the cortical bone (caveats)
Cellularity - 30:70 and 70:30 Marrow: fat :: hyper/hypocellular Myeloid: erythroid :: wide range
Myeloid lineagelocalisation, differentiation, maturation Erythroid lineagelocalisation, maturation Megakaryocyteslocalisation, number, morphology Other-haematopoetic cells Lymphoid, Plasma cells, mast cells Non-haematopoetic cells Metastases Bony trabeculae ; vessels Special stains- Reticulin (Perls, Giemsa)
The Christie NHS Foundation Trust
The Christie NHS Foundation Trust
Bone marrow trephine reporting Semi-quantitative Grading of Bone Marrow Fibrosis Grade
Description
0
Scattered linear reticulin fibers with no intersections (crossovers), corresponding to normal bone marrow
1
Loose network of reticulin with many intersections, especially in perivascular areas
2
Diffuse and dense increase in reticulin with extensive intersections, occasionally with focal bundles of collagen or focal osteosclerosis
3
Diffuse and dense increase in reticulin with extensive intersections and coarse bundles of collagen, often associated with osteosclerosis
The Christie NHS Foundation Trust Ref. Jaffe E, et al. Haematopathology. Elsevier, 2011.
Bone marrow trephine reporting MYELOID NEOPLASMS Myeloproliferative Neoplasms (CML,PV, ET, PM, mastocytosis,others) Common characteristics hypercellular ; progression with time to acute leukaemia; increasing fibrosis
• CML- CP : Marked granulocytic differentiation (inc. var. increased eosinophils, basophils); left-shift; Megakaryocytes increased smaller hypolobate BCR-ABL1
• PV : prominent erythroid differentiation Florid megakaryocytic proliferation- larger hypo-hyperlobated, loose clusters Large dilated sinuses filled with red blood cells JAK2V617F
The Christie NHS Foundation Trust
Bone marrow trephine reporting MYELOID NEOPLASMS Myeloproliferative Neoplasms (CML,PV, ET, PM, mastocytosis,others) Common characteristics hypercellular ; progression with time to acute leukaemia; increasing fibrosis
•
Essential Thrombocythemia (ET): megakaryocytic proliferation - giant forms with nuclear atypia (less pleomorphic than PV/PM) , ‘staghorn’ nuclei , clusters, near sinuses JAK2V617F, MPL
•
Primary Myelofibrosis: prefibrotic and fibrotic stages well-vascularized fibrosis bizarre megakaryocytes; ‘cloud-like’, bare nuclei, dense clusters, adjacent to endosteum/sinusoids JAK2V617F
•
Mast Cell Disease paratrabecular/ perivascular infiltrates or intertrabecular nodules multifocal, dense infiltrates (>15m.c. in aggregate) atypical or spindle shaped (>25%) IHC (CD117, CD2, CD25, tryptase) KIT-mutation D816V
The Christie NHS Foundation Trust
Bone marrow trephine reporting MYELOID NEOPLASMS MD Syndromes/ neoplasms (RCUD, RCMD, RARS, RAEB, isolated 5q, others) Myelodysplastic features (all three/two/one cell line affected) • Erythroblasts: Nuclear abnormalities- binucleate/ megaloblastic ; disrupted colonies, single stage of maturation • Myeloid: Nuclear abnormalities and decreased granularity ALIPs • Megakaryocytes: Micro-/ Mononuclear/Naked nuclei paratrabecular • Background haemosiderin The Christie NHS Foundation Trust
Bone marrow trephine reporting MYELOID NEOPLASMS - MD Syndromes/ neoplasms
Dyshematopoietic features
dyserythropoiesis & increase in immature mononuclear cells
(ref. images - dako)
dyserythropoiesis, increase in immature cells (presumably of myeloid lineage) (arrows) and granular deposits of hemosiderin
The Christie NHS Foundation Trust
Bone marrow trephine reporting MYELOID NEOPLASMS - MD Syndromes/ neoplasms
Dyshematopoietic features
aggregates of abnormally localized immature precursor (ALIP) cells
Grouped dysmorphic (hypolobated) megakaryocytes (arrow),
The Christie NHS Foundation Trust
Bone marrow trephine reporting PITFALLS HIV Marrow •MDS-like features (all three lineages)- in 3/4th •Other changes (kaposi’s sarcoma)
The Christie NHS Foundation Trust
Bone marrow trephine reporting MYELOID NEOPLASMS Myelodysplastic/MPN (CMML and others) CMML: Monocyte count absent specific cytogenetic abN (BCR-ABL/PDGFR) dysplasia or clonal abN or persistent unexplained monocytosis CD123, CD163
The Christie NHS Foundation Trust
Bone marrow trephine reporting MYELOID NEOPLASMS Acute myeloid leukaemia (recurrent genetic abn. [APML]/ MDS-/ Therapy-related, AML-NOS, myeloid sarcoma, Blastic plasmacytoid dendritic)
• 20% blasts in marrow • Specific cytogenetic abnormality • APML t(15,17)
The Christie NHS Foundation Trust
Bone marrow trephine reporting PITFALLS Megaloblastic Marrow
giant metamyelocytes and small megakaryocytes with hyperlobated nuclei
Aplastic Anemia • D/D Hypocellular MDS/AML look at the cells - blasts
The Christie NHS Foundation Trust
Bone marrow trephine reporting LYMPHOID NEOPLASMS Acute Lymphoblastic Leukemia PITFALLmonotonous, ‘small’ B-cell and T-cell markers Ki-67 TdT Lineage markers
The Christie NHS Foundation Trust
Bone marrow trephine reporting LYMPHOID NEOPLASMS Context: • • • •
CLL
Staging marrows (n.b. discordance) Primary diagnosis Splenomegaly, FBC/ peripheral smear WNL
Patterns of infiltration: Normal Interstitial (CLL ) Nodular (CLL ; d/d reactive) Intra-sinusoidal Paratrabecular (FL) Diffuse/ packed (advanced stage with dense infiltrate)
Hairy cell leukemia: Annexin1, CD123, CD103, CD68 and DBA.44, BRAF V600E mutations
FL
HCL
Lymphoplasmacytic lymphoma: range of differentiation between lymphocytes and plasma cells; dutcher bodies
Plasma cell neoplasm: >10% Plasma cells, clonal
LPL Other NHL’s: DLBCL etc HL: staging ; levels for mononuclear cells; appropriate background The Christie NHS Foundation Trust
Bone marrow trephine reporting PITFALLS Benign vs neoplastic lymphoid aggregates in the bone marrow
The Christie NHS Foundation Trust